A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 µm to about 5 µm. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.
A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 µm to about 10 µm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles.
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
The subject technology relates to pulmonary delivery of dry powder formulations of nonsteroidal anti-inflammatory drugs (NSAIDs), such as acetylsalicylic acid. The subject technology further relates to dry powder formulations of NSAIDs with an improved stability.
Disclosed herein is a device for the delivery of a dry powdered or aerosolized substance (e.g., medication) to a user via inhalation. Delivery of the dry powdered substance is performed using an inhalation device having an inhalation tube and a hollow extension housing an assembly of components including an impeller, a puncturing device and a dry powder container. The inhalation tube, extension and assembly are configured such that a user inhaling a breath from an end of the inhalation device creates a negative pressure on the container of dry powdered substance thereby drawing the dry powdered substance from the container into the user's lungs. The delivery of the dry powder through the inhalation device is facilitated by the puncturing device that punctures the dry powder container, the impeller that directs the flow of air and the particular configuration of the extension and the inhalation tube.
A respirable dry powder including acetvisalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μιη to about 10 μηι. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A respirable dry powder including acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
A respirable dry powder including acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 µm to about 10 µm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
Methods for reducing the risk of a thromboembolic event, and a related drug delivery system are provided. In some embodiments, a dose of acetylsalicyhc acid can be provided in powder form to a patient using a dry powder inhaler. The dose can be effective to reduce a risk of a thromboembolic event in a patient. A dry powder inhaler used for the method can have a mouthpiece, a reservoir for receiving the dose of acetylsalicyhc acid, and an actuation member for making available the dose of acetylsalicyhc acid for inhalation by a patient through the mouthpiece.
A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
Methods for reducing the risk of a thromboembolic event, and a related drug delivery system are provided. In some embodiments, a dose of acetylsalicyhc acid can be provided in powder form to a patient using a dry powder inhaler. The dose can be effective to reduce a risk of a thromboembolic event in a patient. A dry powder inhaler used for the method can have a mouthpiece, a reservoir for receiving the dose of acetylsalicyhc acid, and an actuation member for making available the dose of acetylsalicyhc acid for inhalation by a patient through the mouthpiece.
A01N 37/36 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
A device for delivery of a substance to an external auditory canal and/or nasal cavity can include a reservoir, an aerosolizing mechanism, a nozzle, and a retaining member. The reservoir can contain the substance. The aerosolizing mechanism can suspend a dose of the substance, as particulates for example, in a gas. The nozzle can include a lumen, an outer surface, and a distal end. The lumen can be sized to permit movement of the gas and particulates therethrough. The retaining member can be configured to be attached to the nozzle proximate the distal end of the nozzle, projecting laterally from the lumen of the nozzle, shaped to engage the ear and/or nostril, and can include a passage therethrough to allow passage of gas and to inhibit passage of at least some of the particulates.
patents
